$Tempest Therapeutics (TPST.US)$ unfucking believable
1
72329785
commented on
$Ensysce Biosciences (ENSC.US)$ why no circuit breaker???
1
3
72329785
commented on
glad I sold yesterday at 1.19
1
1
72329785
liked
$Cemtrex (CETX.US)$ waiting that huge candle 🙏🙏🙏
3
5
72329785
liked
$Aditxt (ADTX.US)$
Aditxt Completes Third Parent Equity Investment Under Amended And Restated Merger Agreement With Evofem
Aditxt (NASDAQ: ADTX) has completed the Third Parent Equity Investment in Evofem Biosciences (OTCQB: EVFM) under their Amended and Restated Merger Agreement. Aditxt purchased 460 shares of Evofem Series F-1 Convertible Preferred Stock for $460,000, bringing their total investment to $1.72 million. Aditxt plans to complete the Fourth Parent Equity Investment of $2.28 milli...
Aditxt Completes Third Parent Equity Investment Under Amended And Restated Merger Agreement With Evofem
Aditxt (NASDAQ: ADTX) has completed the Third Parent Equity Investment in Evofem Biosciences (OTCQB: EVFM) under their Amended and Restated Merger Agreement. Aditxt purchased 460 shares of Evofem Series F-1 Convertible Preferred Stock for $460,000, bringing their total investment to $1.72 million. Aditxt plans to complete the Fourth Parent Equity Investment of $2.28 milli...
5
72329785
liked and commented on
$Biomea Fusion (BMEA.US)$
FDA Lifts Clinical Hold on BMF-219 in Type 2 and Type 1 Diabetes Trials
Biomea Fusion, Inc. (Nasdaq: BMEA) announced that the FDA has lifted the clinical hold on its ongoing Phase I/II clinical trials of BMF-219, an investigational covalent menin inhibitor, for type 2 and type 1 diabetes(COVALENT-111 and COVALENT-112).
The company's CEO, Thomas Butler, expressed confidence in BMF-219 as a novel, first-in-class agent for diabetes treatment, noting that safety concern...
FDA Lifts Clinical Hold on BMF-219 in Type 2 and Type 1 Diabetes Trials
Biomea Fusion, Inc. (Nasdaq: BMEA) announced that the FDA has lifted the clinical hold on its ongoing Phase I/II clinical trials of BMF-219, an investigational covalent menin inhibitor, for type 2 and type 1 diabetes(COVALENT-111 and COVALENT-112).
The company's CEO, Thomas Butler, expressed confidence in BMF-219 as a novel, first-in-class agent for diabetes treatment, noting that safety concern...
1
2
72329785
liked
$Intuitive Machines (LUNR.US)$ ignore the naysayers.
3